Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Distribution of RGS9-2 in neurons of the mouse striatum.

Journal of neurochemistry | Feb 20, 2010

Regulators of G protein signaling (RGS) proteins negatively modulate G protein-coupled receptor (GPCR) signaling activity by accelerating G protein hydrolysis of GTP, hastening pathway shutoff. A wealth of data from cell culture experiments using exogenously expressed proteins indicates that RGS9 and other RGS proteins have the potential to down-regulate a significant number of pathways. We have used an array of biochemical and tissue staining techniques to examine the subcellular localization and membrane binding characteristics of endogenous RGS9-2 and known binding partners in rodent striatum and tissue homogenates. A small fraction of RGS9-2 is present in the soluble cytoplasmic fraction, whereas the majority is present primarily associated with the plasma membrane and structures insoluble in non-ionic detergents that efficiently extract the vast majority of its binding partners, R7BP and G(beta5). It is specifically excluded from the cell nucleus in mouse striatal tissue. In cultured striatal neurons, RGS9-2 is found at extrasynaptic sites primarily along the dendritic shaft near the spine neck. Heterogeneity in RGS9-2 detergent solubility along with its unique subcellular localization suggests that its mechanism of membrane anchoring and localization is complex and likely involves additional proteins beside R7BP. An important nuclear function for RGS9-2 seems unlikely.

Pubmed ID: 19912469 RIS Download

Mesh terms: Animals | Cells, Cultured | Cerebral Cortex | Coculture Techniques | Corpus Striatum | Dopamine and cAMP-Regulated Phosphoprotein 32 | GTP-Binding Protein beta Subunits | Glutamate Decarboxylase | Membrane Microdomains | Mice | Mice, Inbred C57BL | Mice, Knockout | Microfilament Proteins | Nerve Tissue Proteins | Neurons | Protein Binding | RGS Proteins | Rats | Rats, Sprague-Dawley | Subcellular Fractions | Synapses | Transcription Factor TFIID

Research resources used in this publication

Research tools detected in this publication

Data used in this publication

None found

Associated grants

  • Agency: NIDA NIH HHS, Id: R01-DA15189
  • Agency: NEI NIH HHS, Id: R01 EY007981
  • Agency: NEI NIH HHS, Id: R01 EY011900
  • Agency: NIDDK NIH HHS, Id: T32 DK007696
  • Agency: NEI NIH HHS, Id: R01-EY11900
  • Agency: NIDA NIH HHS, Id: R01 DA015189
  • Agency: NINDS NIH HHS, Id: R01 NS055339
  • Agency: NEI NIH HHS, Id: P30 EY002520
  • Agency: NIDDK NIH HHS, Id: T32- DK007696
  • Agency: NINDS NIH HHS, Id: R01-NS055339

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


A national mouse monoclonal antibody generating resource for biochemical and immunohistochemical applications in mammalian brain. NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the initial NeuroMab screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e. NeuroMabs): for immunocytochemical-based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks. The NeuroMab facility was initially funded with a five-year U24 cooperative grant from NINDS and NIMH. The initial goal of the facility for this funding period is to generate a library of novel NeuroMabs against neuronal proteins, initially focusing on membrane proteins (receptors/channels/transporters), synaptic proteins, other neuronal signaling molecules, and proteins with established links to disease states. The scope of the facility was expanded with supplements from the NIH Blueprint for Neuroscience Research to include neurodevelopmental targets, the NIH Roadmap for Medical Research to include epigenetics targets, and NIH Office of Rare Diseases Research to include rare disease targets. These NeuroMabs will then be produced on a large scale and made available to the neuroscience research community on an inexpensive basis as tissue culture supernatants or purified immunoglobulin by Antibodies Inc. The UC Davis/NIH NeuroMab Facility makes NeuroMabs available directly to end users and is unable to accommodate sales to distributors for third party distribution. Note, NeuroMab antibodies are now offered through antibodiesinc.


View all literature mentions


An Antibody supplier


View all literature mentions